Treatment with acmopatide (CT-868), a dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA), improved glycemic management while reducing weight, insulin dose, and blood pressure in a phase 2 clinical trial of adults living with type 1 diabetes and obesity
This approach will help you significantly improve your patient acquisition and retention rates
A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
Biologically active compounds like phospholipids can also increase the bioavailability or absorption of glutathione in your body
For example, liraglutide, when we're talking about Saxenda for weight loss, you're more in the 5 to 10% weight loss category, but the minute you move up into semaglutide or Wegovy, you're now entering more like 10 to 20%
Gastrointestinal Conditions BPC-157 was originally isolated from gastric juice, and its most robust preclinical evidence involves gastrointestinal healing
